Pharmesis International Ltd. (BFK) Jumped 12.07% on May 17

May 17, 2018 - By Rodney Autry

Shares of Pharmesis International Ltd. (SGX:BFK) last traded at 0.325, representing a move of 12.07%, or 0.035 per share, on volume of 5,100 shares. After opening the trading day at 0.205, shares of Pharmesis International Ltd. traded in a close range. Pharmesis International Ltd. currently has a total float of 23.00 million shares and on average sees 326 shares exchange hands each day. The stock now has a 52-week low of 0.161 and high of 0.33.

SGX: SE Asia’s Driver of Growth

In the latest list of the top Asian markets in terms of corporate governance issued biannually by CG Watch, Singapore has ranked first, beating Hong Kong by two points with a score of 67 points. This puts the Singapore Exchange (SGX) in a more competitive global position because investors are further encouraged by excellent corporate governance. It gives Pharmesis International Ltd. and other companies inside SGX lists privileges.

Good corporate governance reflects a nation’s ability to maximize resources and opportunities, to boost investors’ confidence in its long-term economic success, and to back healthy market competition.

Corporate governance is highly associated with foreign direct investment (FDI), which is essential in national economic growth. Similarly, high FDI inflow in Singapore through the SGX can lift the Southeast (SE) Asian economy as a whole, too. It is without a doubt that Singapore is already one of the biggest economic growth contributors in the region, thanks to the SGX. And Pharmesis International Ltd. is the part of this growth.

SGX Then

The SGX was instituted in December 1999 after the Singapore International Monetary Exchange and the Stock Exchange of Singapore— the two leading stock exchange platforms in Singapore back then— had merged to create a consolidated stock exchange platform in Singapore.

Singapore Exchange Limited owns and operates the SGX is, which is traded on the stock exchange platform as well. Like any other stock exchange platforms, the SGX broadly features all kinds of trading instruments.

A year after its establishment, it already became a publicly traded company, serving as a component of the MSCI Singapore Free Index and the Strait Times Index (STI), which tracks the performance of top 30 SGX companies in terms of market capitalization quarterly.

SGX Now

Regular session during business days lasts from 9:00 a.m. until 5:00 p.m. while pre-market session lasts from 8:30 a.m. until 8:59 p.m. Extended trading lasts until 5:05 p.m. before the market officially concludes the session at 5:06 p.m.

As of January 2009, there are 455 domestic companies and 313 international companies listed on the SGX. Over 90 of these companies have a market capitalization of more than S$1 billion each. Undoubtedly, the listing still continues to expand.

With a solid performance through the years, more and more international companies are compelled to enter the Singaporean market, hoping to take advantage of the tremendous growth opportunities in the country and of the optimistic trading environment.

Over the past five years, there are three companies listed on the SGX that have demonstrated interesting growth performance. These include Comfortdelgro Corporation Limited (SGX:C52),Thai Beverage Public Company Limited (SGX:Y92) and SATS Ltd (SGX:S58). During the said five-year period, Thai Beverage has generated a 216% return; Comfortdelgro has generated a 123% return; and SATS has generated a 119% return. Good and reliable return attracts more clients to Pharmesis International Ltd..

As it aims to transform the region’s thriving economy, the SGX remains to be one of the best and the fastest-growing stock exchange platforms in the world. Needless to point out, the SGX is one of SE Asia’s key to becoming the next world leader in economy such as North America.

Pharmesis International Ltd., an investment holding company, researches, develops, produces, sells, and markets western medicines and traditional Chinese medicine formulated products for hospitals and medical institutions in the People's Republic of China. The company has market cap of $7.48 million. The firm provides prescribed products and over-the-counter drugs. It currently has negative earnings. It offers western medicine products under the brand name of Kinna, including Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Compound Procaine hydrochloride to treat arteriosclerosi, menopausal symptoms, dyspepsia, and adynamia; Lianpushuangqing for acute inflammation; AFenKa to treat migraine, relieves pain, headache, nasosinusitis, cold, muscle pain, menstrual pain, toothache, and arthritis; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for the rheumatoid arthritis and other rheumatic diseases treatment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.